• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Ann Intensive Care . Long-term survival of mechanically ventilated patients with severe COVID-19: an observational cohort study

tetano

Editor, Senior Moderator
Ann Intensive Care


. 2021 Oct 2;11(1):143.
doi: 10.1186/s13613-021-00929-y.
Long-term survival of mechanically ventilated patients with severe COVID-19: an observational cohort study


Oscar Peñuelas[SUP] 1 2 [/SUP], Laura Del Campo-Albendea[SUP] 3 [/SUP], Amanda Lesmes González de Aledo[SUP] 4 [/SUP], José Manuel Añón[SUP] 5 6 [/SUP], Carmen Rodríguez-Solís[SUP] 7 [/SUP], Jordi Mancebo[SUP] 8 [/SUP], Paula Vera[SUP] 8 [/SUP], Daniel Ballesteros[SUP] 9 [/SUP], Jorge Jiménez[SUP] 7 [/SUP], Emilio Maseda[SUP] 10 [/SUP], Juan Carlos Figueira[SUP] 5 6 [/SUP], Nieves Franco[SUP] 11 [/SUP], Ángela Algaba[SUP] 12 [/SUP], Juan Pablo Avilés[SUP] 13 [/SUP], Ricardo Díaz[SUP] 13 [/SUP], Beatriz Abad[SUP] 14 [/SUP], Alfonso Canabal[SUP] 14 [/SUP], Ana Abella[SUP] 15 [/SUP], Federico Gordo[SUP] 15 [/SUP], Javier García[SUP] 16 [/SUP], Jessica García Suarez[SUP] 16 [/SUP], Jamil Cedeño[SUP] 17 [/SUP], Basilia Martínez-Palacios[SUP] 18 [/SUP], Eva Manteiga[SUP] 18 [/SUP], Óscar Martínez[SUP] 19 [/SUP], Rafael Blancas[SUP] 19 [/SUP], Tommaso Bardi[SUP] 20 [/SUP], David Pestaña[SUP] 20 [/SUP], José Ángel Lorente[SUP] 7 5 [/SUP], Alfonso Muriel[SUP] 3 [/SUP], Andrés Esteban[SUP] 7 [/SUP], Fernando Frutos-Vivar[SUP] 7 [/SUP]



Affiliations

Abstract

Background: Information is lacking regarding long-term survival and predictive factors for mortality in patients with acute hypoxemic respiratory failure due to coronavirus disease 2019 (COVID-19) and undergoing invasive mechanical ventilation. We aimed to estimate 180-day mortality of patients with COVID-19 requiring invasive ventilation, and to develop a predictive model for long-term mortality.
Methods: Retrospective, multicentre, national cohort study between March 8 and April 30, 2020 in 16 intensive care units (ICU) in Spain. Participants were consecutive adults who received invasive mechanical ventilation for COVID-19. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection detected in positive testing of a nasopharyngeal sample and confirmed by real time reverse-transcriptase polymerase chain reaction (rt-PCR). The primary outcomes was 180-day survival after hospital admission. Secondary outcomes were length of ICU and hospital stay, and ICU and in-hospital mortality. A predictive model was developed to estimate the probability of 180-day mortality.
Results: 868 patients were included (median age, 64 years [interquartile range [IQR], 56-71 years]; 72% male). Severity at ICU admission, estimated by SAPS3, was 56 points [IQR 50-63]. Prior to intubation, 26% received some type of noninvasive respiratory support. The unadjusted overall 180-day survival rates was 59% (95% CI 56-62%). The predictive factors measured during ICU stay, and associated with 180-day mortality were: age [Odds Ratio [OR] per 1-year increase 1.051, 95% CI 1.033-1.068)), SAPS3 (OR per 1-point increase 1.027, 95% CI 1.011-1.044), diabetes (OR 1.546, 95% CI 1.085-2.204), neutrophils to lymphocytes ratio (OR per 1-unit increase 1.008, 95% CI 1.001-1.016), failed attempt of noninvasive positive pressure ventilation prior to orotracheal intubation (OR 1.878 (95% CI 1.124-3.140), use of selective digestive decontamination strategy during ICU stay (OR 0.590 (95% CI 0.358-0.972) and administration of low dosage of corticosteroids (methylprednisolone 1 mg/kg) (OR 2.042 (95% CI 1.205-3.460).
Conclusion: The long-term survival of mechanically ventilated patients with severe COVID-19 reaches more than 50% and may help to provide individualized risk stratification and potential treatments.
Trial registration: ClinicalTrials.gov Identifier: NCT04379258. Registered 10 April 2020 (retrospectively registered).

Keywords: ARDS; COVID-19; Coronavirus disease 2019; Intensive care unit; Invasive mechanical ventilation; Mortality; Noninvasive ventilation; Pneumonia; SARS-CoV-2.
 
Back
Top Bottom